Increasing productivity in cell and gene therapy bioprocessing with fast and reliable immunoassays

In this white paper, Gyros Protein Technologies discusses the crucial role of immunoassay platforms in ensuring the timely release of safe and effective cell and gene therapeutics. Choosing the right platform involves considering various factors, including robustness, quick data generation from limited samples, support for rapid method development, and flexibility for novel assays. Automation and walk-away systems are essential for reducing manual labor and minimizing errors, allowing personnel to focus on more critical tasks. Additionally, ready validation and software that enables 21 CFR Part 11 compliance are necessary to meet regulatory guidelines.